ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 112 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $161,541 | -28.5% | 19,968 | +39.3% | 0.00% | -100.0% |
| Q4 2022 | $225,792 | +28.3% | 14,336 | +28.4% | 0.00% | – |
| Q3 2022 | $176,000 | +17.3% | 11,162 | +3.8% | 0.00% | – |
| Q2 2022 | $150,000 | -19.4% | 10,752 | -0.6% | 0.00% | – |
| Q1 2022 | $186,000 | -35.9% | 10,816 | -45.7% | 0.00% | -100.0% |
| Q4 2021 | $290,000 | -73.0% | 19,935 | -66.6% | 0.00% | -50.0% |
| Q3 2021 | $1,075,000 | +102.4% | 59,696 | +97.3% | 0.00% | +100.0% |
| Q2 2021 | $531,000 | +93.8% | 30,263 | +184.8% | 0.00% | – |
| Q3 2017 | $274,000 | -6.8% | 10,625 | -1.8% | 0.00% | – |
| Q2 2017 | $294,000 | – | 10,825 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |